CADTH has received notice of a pending submission from Novartis for pasireotide pamoate (Signifor LAR) for patients with acromegaly. For information about the patient input process or for additional instructions, please see the patient input page of the CADTH website. Note that typically only patient groups may submit input; however, there is currently a pilot process for receiving patient input submissions from individual patients and caregivers (runs until August 3, 2015).

For more details, go to: http://www.cadth.ca/en/products/cdr/patient-group-input-form/403